Regulatory Sciences
Regulatory strategy and submission support for INDs, BLAs, NDAs, and global regulatory filings with FDA and international agencies.
Key Capabilities
- IND preparation and submission strategy
- BLA and NDA preparation and submission
- FDA meeting preparation (Pre-IND, End-of-Phase 2, Pre-BLA)
- Regulatory strategy for biologics and small molecules
- Global regulatory strategy (FDA, EMA, PMDA)
- Risk management and REMS strategy
- Post-approval regulatory support
Our Approach
Regulatory strategy is the backbone of successful drug development. Bionavigen's regulatory consulting team has supported over 15 BLA and NDA submissions, providing the expertise needed to navigate complex regulatory pathways.
We help clients develop comprehensive regulatory strategies that align with FDA expectations and maximize the probability of approval. Our team has extensive experience with FDA interactions, including Pre-IND, End-of-Phase 2, and Pre-BLA meetings.
Our regulatory consultants work as an integrated part of your development team, providing strategic guidance and hands-on support for all aspects of regulatory submissions and agency interactions.